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Abstract 
 
 Acquired platinum resistance is a serious problem in the treatment of ovarian 
carcinomas. However, the mechanism of the drug resistance has not been elucidated. 
Here, we show functional significance of restoration of BRCA2 protein by secondary 
BRCA2 mutations in acquired drug resistance of BRCA2-mutated ovarian carcinoma. 
Three ovarian cancer cell lines (PEO1, PEO4 and PEO6) were derived from a BRCA2 
mutation (5193C>G (Y1655X)) carrier with ovarian carcinoma with acquired cisplatin 
resistance and a secondary BRCA2 mutation (5193C>T (Y1655Y)) that canceled the 
inherited mutation. PEO1 was BRCA2-deficient and sensitive to cisplatin and a 
poly(ADP-ribose) polymerase inhibitor, AG14361, while PEO4 was resistant. PEO4 and 
PEO6, derived from ascites at the time of relapse with cisplatin resistance, had the 
secondary mutation and were BRCA2-proficient. In vitro cisplatin/AG14361 selection of 
PEO1 led to restoration of BRCA2 due to another secondary BRCA2 mutation. BRCA2 
depletion sensitized BRCA2-restored PEO1 clones and PEO4 to cisplatin/AG14361. 
Thus, restoration of BRCA2 due to secondary BRCA2 mutation is involved in acquired 
drug resistance of BRCA2-mutated ovarian carcinoma. 
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Introduction  
 
 Chemotherapy with platinum compounds, such as cisplatin and carboplatin, is 
initially effective for most patients with ovarian carcinomas. However, the majority 
eventually become refractory to platinum treatment (1). BRCA2 is a tumor suppressor 
gene responsible for familial breast/ovarian cancer. BRCA2 controls homologous 
recombination by regulating RAD51 (2, 3). BRCA1- and BRCA2- (BRCA1/2) deficient 
cells are hypersensitive to cisplatin and poly(ADP-ribose) polymerase (PARP) inhibitors 
(4-6). Tumors from heterozygous BRCA1/2 mutation carriers usually show loss of 
heterozygosity at the BRCA1/2 loci and are presumed to be BRCA1/2 deficient (7-9). 
Consistently, women with BRCA1/2-mutated ovarian carcinoma have a better prognosis 
than those without BRCA1/2 mutation if they receive platinum-based therapy (10), and 
PARP inhibitors are becoming a therapeutic option in BRCA1/2-mutated cancers (6). 
However, even patients with BRCA1/2-mutated ovarian carcinoma frequently experience 
recurrence with platinum resistance. 
 Acquired resistance to cisplatin in vitro in a BRCA2-mutated pancreatic cancer 
cell line, Capan-1, is mediated by secondary mutations in BRCA2 that restore the 
wild-type BRCA2 reading frame (11, 12). Three cases of platinum-resistant recurrent 
ovarian cancer with secondary BRCA2 mutation have been reported (11, 12), suggesting 
involvement of secondary BRCA2 mutation in platinum-resistance of ovarian cancer. 
However, because of lack of a human BRCA2-deficient ovarian cancer cell line model, 
the functional significance of secondary BRCA2 mutations in ovarian cancer has not been 
demonstrated. Here, we report the first human BRCA2-deficient ovarian cancer cell line 
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model and the functional significance of secondary BRCA2 mutations in acquired drug 
sensitivity of ovarian cancer cells. 
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Materials and Methods 
 
Cell lines. Ovarian cancer cell lines (PEO1, 2008, 2008+FANCF, C13*, OAW42, 
TOV-21G, TOV-112D, OV-90, PA-1, ES-2, Caov-3, SK-OV-3, SW626, 
NIH:OVCAR-3, DOV13, RMG-1, A2780, IGROV-1, OVCAR-5, OVCAR-8, A1847, 
OAW28, COLO720E, 59M) (13) and PEO6 (14) were described previously. PEO1 and 
PEO4 (15) were gifts from Dr. S. Williams (Fox Chase Cancer Center). Cell lines were 
grown in DMEM with 10% fetal calf serum in a humidified 5% CO2-containing 
atmosphere at 37oC. Gamma irradiation was delivered using a JL Shepherd Mark I 
Cesium Irradiator (JL Shepherd & associates, San Fernando, CA). PEO1 cells were 
selected in cisplatin (4µM) (Sigma, St. Louis, MO) or a PARP inhibitor (AG14361 
(4µM), a gift of Pfizer) -containing medium for 4 weeks. Drug-resistant colonies were 
picked and expanded in normal medium. Initially, 14 cisplatin-selected clones were 
picked, but three of them (C4-3, C4-8, and C4-9) were omitted, because C4-8 and C4-9 
did not grow and C4-3 turned out to be a mixed population. Therefore, 11 
cisplatin-selected clones were analyzed. Initially, 12 AG14361-selected clones were 
picked, but nine of them were omitted, because they did not grow. Therefore, three 
AG14361-selected clones were analyzed. 
Western blot analysis and immunofluorescence microscopy. BRCA2 western blotting 
using anti-BRCA2 Ab-1 (OP95, EMD Biosciences) and Ab-2 (PC146, EMD 
Biosciences) and immunostaining for RAD51 were done as described (11).  
BRCA2 sequencing. Extraction of genomic DNA and RNA, reverse transcription, PCR 
and sequencing of BRCA2 were done as described (11). All nucleotide numbers refer to 
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the cDNA human sequence of BRCA2 (accession no. U43746; version U43746.1 GI: 
1161383) (GenBank). 
Drug sensitivity assays. Cisplatin/AG14361 sensitivity of cells was determined by crystal 
violet assay as described (11).  
siRNA transfection. Expression of BRCA2 was knocked down by transient transfection 
of siRNA directed against BRCA2 (#1 (5’-AACAACAATTACGAACCAAAC-3’), #2 
(5'-CAGGACACAATTACAACTAAA-3')) and negative control 
(5’-AATTCTCCGAACGTGTCACGT-3’) as described (11). Final concentration of 
siRNA was 50nM. Two or three days after transfection, cells were used for drug 
sensitivity assays, western blotting and immunofluorescence experiments.  
In vitro homologous recombination assay. V-C8-DR-GFP cells were transfected with 
either pcDNA3.1 vector, pcBAsce1 vector containing the I-SceI restriction endonuclease 
gene, or pcBAsce1 plus various FLAG tagged BRCA2-pcDNA3.1 constructs. After 72 h, 
cells were harvested and the number of green fluorescent protein (GFP)–expressing cells 
was assessed by flow cytometry. In parallel, we determined transfection/expression 
efficiency for BRCA2 by fluorescently labeling cells from these transfection experiments 
with an anti-FLAG antibody and counting the number of FLAG-BRCA2–expressing cells 
per 1,000 cells using a fluorescence microscope. The ratio of GFP-expressing cells 
induced by wild-type or mutant BRCA2 compared with vector control in the homologous 
recombination assay was then plotted after adjustment for transfection efficiency (11). 
Clinical specimens. Tissue samples from the BRCA2-mutated ovarian cancer patient 
from whom the ovarian cancer cell lines, PEO1, PEO4 and PEO6, were derived were 
obtained from the University of Edinburgh. The study was approved by Institutional 
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Review Boards of Fred Hutchinson Cancer Research Center.  
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Results and Discussion 
 
 We tested 25 ovarian cancer cell lines for expression of BRCA2 protein and found 
that BRCA2 protein was undetectable in PEO1 (Fig 1A). PEO1 was derived from the 
ascites of a patient with poorly differentiated ovarian serous adenocarcinoma that was still 
clinically responsive to cisplatin at the first relapse (14, 15). The clinical course of this 
patient is summarized in Fig 1B. Remarkably, in two ovarian cancer cell lines (PEO4 and 
PEO6) derived from the same patient obtained when her carcinoma had acquired clinical 
cisplatin resistance, BRCA2 protein was detectable (Fig 1A). PEO1 was sensitive to 
cisplatin and a PARP inhibitor (AG14361), while PEO4 was resistant (Figs 1C and 2D), 
consistent with the BRCA2 protein expression status.  
 The patient turned out to be a heterozygous carrier of BRCA2.5193C>G (Y1655X) 
nonsense mutation (Fig 1D). Consistently, PEO1 had the hemizygous nonsense mutation 
(5193C>G). PEO1 is the first and only human BRCA2-deficient ovarian cancer cell line 
described, to the best of our knowledge. 
 Interestingly, PEO4 and PEO6 had a silent mutation (5193C>T, Y1655Y) instead 
(Fig 1D). In neoplastic cells in the ascites from which PEO4 and PEO6 were derived, at the 
relapse with clinical cisplatin resistance, 5193C>T was also detected. Thus, the secondary 
mutation (5193C>T) which canceled the inherited nonsense mutation (5193C>G) occurred 
in vivo.  
 Next, we selected PEO1 cells in cisplatin-containing medium (4µM) for four weeks 
in vitro and obtained 11 clones out of two million cells. Eight of them restored BRCA2 
protein (Fig 2A) and had a secondary BRCA2 mutation (5192A>T) (Figs 2B and 2C). This 
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mutation is a single base pair substitution that changed the stop codon into an amino acid 
coding triplet leading to the restoration of the open reading frame (5192A>T; 5193C>G, 
Y1655L).  
 The eight BRCA2-restored PEO1 clones and PEO4 were cisplatin- and 
AG14361-resistant compared to parental PEO1 (Fig 2D), consistent with functionality of 
the restored BRCA2 proteins. Two of the three clones without BRCA2 restoration (C4-4, 
and C4-11) were cisplatin resistant, while the other clone (C4-13) was only slightly 
resistant. One of the cisplatin-resistant clones without restored BRCA2 (C4-4) was still 
sensitive to AG14361, consistent with the lack of BRCA2. Two cisplatin-resistant clones 
without restored BRCA2 (C4-11 and C4-13) showed intermediate sensitivity to AG14361, 
suggesting the existence of alternative mechanisms for the drug resistance. 
 Next, we analyzed the homologous recombination-based DNA double-strand-break 
repair function of the novel BRCA2 proteins using an I-SceI-dependent DR-GFP reporter 
assay in BRCA2-deficient V-C8 cells (16, 17) (Fig 3A and Supplemental Fig S1). In this 
assay, GFP expression correlates with the occurrence of homologous recombination. 
Transfection of a wild-type BRCA2 construct or constructs with the secondary BRCA2 
mutations ((5192A>T; 5193C>G, Y1655L) or (5193C>T, Y1655Y)) resulted in seven to 
eight-fold more GFP-positive cells compared to control, whereas transfection of the 
5193C>T (Y1655X) mutant construct resulted in impaired induction of GFP-positive 
cells. These results indicate that the secondary-mutated BRCA2 proteins efficiently 
promote homologous recombination. 
  Functional BRCA2 is required for ionizing radiation-induced RAD51 foci 
formation (4). Consistently, in parental PEO1 cells and the three BRCA2-non-restored 
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PEO1 clones, ionizing radiation-induced RAD51 foci formation was severely impaired 
(Fig 3B). In contrast, it was restored in the eight BRCA2-restored PEO1 clones and in 
PEO4, again suggesting that the secondary-mutated BRCA2 proteins are functional.  
 Next, we depleted BRCA2 in two BRCA2-restored clones (C4-2 and C4-5) and 
PEO4 by siRNA transfection (Fig 4). The BRCA2-depleted cells became sensitive to 
cisplatin/AG14361, indicating that the restored BRCA2 proteins are critical for the 
acquired cisplatin/AG14361 resistance. We confirmed this result using another BRCA2 
siRNA (Supplemental Fig S2). In contrast, BRCA2 siRNA had no effect on drug 
sensitivity of a BRCA2-non-restored clone C4-11 and parental PEO1 (Fig 4).  
 We also selected PEO1 cells in AG14361-containing medium (4µM) for four weeks 
and obtained three clones out of one million cells. These clones restored BRCA2 protein, 
harbored the same secondary mutation (5192A>T), showed restored RAD51 foci 
formation, and were resistant to both cisplatin and AG14361 (Supplemental Fig S3A-D). 
Depletion of BRCA2 sensitized these clones to cisplatin and AG14361 (Supplemental Fig 
S3E-F, S4), indicating that restored BRCA2 was critical for the drug resistance. 
These findings provide compelling evidence that restoration of functional 
BRCA2 protein by secondary BRCA2 mutation has a critical role in acquired 
platinum/PARP inhibitor resistance of BRCA2-mutated ovarian carcinomas. This concept 
has two important clinical implications. First, it suggests the importance of testing 
BRCA2 mutation status in recurrent ovarian carcinomas in BRCA2 mutation carriers to 
predict their response to platinum and PARP inhibitors. Second, it provides a theoretical 
basis for a strategy to overcome platinum/PARP inhibitor resistance. If the mechanism of 
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resistance is restoration of BRCA2, inhibiting BRCA2 function is a logical way to 
re-sensitize the tumor to the drugs.  
 We may be able to apply the concept to other genes regulating DNA repair, such as 
BRCA1 and ATM. Indeed, secondary mutations of BRCA1 occur in BRCA1-mutated 
ovarian cancer with platinum resistance (18). Whether we can apply the concept to 
sporadic ovarian carcinomas with reduced BRCA1 or BRCA2 expression (19) is also an 
important issue to be addressed in the future.  
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Figure Legends 
 
Figure 1. PEO1 is a BRCA2-deficient ovarian cancer cell line. (Full-length blots are 
presented in Supplemental Fig. S5A-B) 
A. BRCA2 western blotting of 25 ovarian cancer cell lines.  
B. Clinical course of the patient with an ovarian cancer from which PEO1, PEO4 and PEO6 
were derived (reconstituted using published information (14, 15)). Timings of collection of 
samples used to generate the cell lines were also shown.  
C. Cisplatin sensitivity assessed by crystal violet assay. 2008 and 2008+FANCF are a 
cisplatin-sensitive and a cisplatin-resistant control, respectively (13). 
D. DNA sequences of BRCA2. In PEO1, a nonsense mutation (5193C>G, Y1655X) was 
observed. In PEO4 and PEO6, a silent mutation on the same base (5193C>T, Y1655Y) 
was observed. In the non-tumor cells of the patient, a heterozygous mutation (5193C>G) 
was detected. In tumor cells from the ascites both at the second relapse and at the terminal 
phase, a secondary BRCA2 mutation (5193C>T) was detected. 
 
Figure 2. Restoration of BRCA2 protein by secondary BRCA2 mutation in 
cisplatin-selected PEO1 clones. (Full-length blots are presented in Supplemental Fig. 
S5C) 
A. BRCA2 western blotting of the 11 clones of PEO1 generated by selecting the cells in the 
presence of cisplatin. Eight PEO1 clones indicated with a single asterisk restored BRCA2 
protein expression. A double asterisk indicates a band presumed to be non-specific. 
B. DNA sequence of BRCA2 in C4-1. In addition to the original mutation (5193C>G), a 
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secondary mutation (5192A>T) was observed. The same mutation was observed in C4-2, 
C4-5, C4-6, C4-7, C4-10, C4-12 and C4-14 (data not shown). The mutation was confirmed 
in cDNAs (data not shown). 
C. Schematic presentation of BRCA2 proteins encoded by transcripts in PEO1 clones, 
PEO4 and PEO6. The secondary genetic changes (shown as white arrow heads) cancel 
the nonsense mutation caused by the original mutation (5193C>G, black arrow heads), 
and the encoded BRCA2 proteins have intact C-terminal regions containing a single 
strand DNA (ssDNA) binding domain and nuclear localization signals (NLS). The 
regions that the BRCA2 antibodies (Ab-1 and Ab-2) recognize are depicted. 
D. Cisplatin/AG14361 sensitivity of the PEO1 clones. Mean values of at least three 
independent experiments ± SEM are shown. All of the cisplatin-selected PEO1 clones 
and PEO4 are cisplatin resistant compared to parental PEO1 (p<0.05, LD50 data were 
compared by unpaired t test). All of the cisplatin-selected PEO1 clones (except for C4-4) 
and PEO4 were AG14361 resistant compared to parental PEO1 (p<0.05, LD50 data were 
compared by unpaired t test). 
 
 
Figure 3. The restored BRCA2 proteins with secondary BRCA2 mutations are 
functional.  
A. Quantitation of homologous recombination induced by I-SceI in VC8-DR-GFP cells 
transiently transfected with wild-type and mutant forms of FLAG-tagged human BRCA2 
cDNA. The proportion of GFP-positive cells for each construct relative to vector control 
is shown (mean ± SEM). Asterisks (*) indicate significant difference with wild-type 
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BRCA2 cDNA-transfected cells (p<0.05, unpaired t test). 
B. Ionizing radiation (IR)-induced RAD51 foci formation is restored in the 
BRCA2-restored PEO1 clones. Indicated cells were irradiated (15 Gy) and fixed 12 hours 
after IR. Cells were immunostained with RAD51 antibody. Representative pictures of 
immunostained cells after IR are shown, together with quantification of the cells with at 
least five RAD51 foci before (-, white bars) and 12 hours after IR (+, grey bars). Mean 
values of at least three independent experiments ± SEM are shown. Asterisks (*) indicate 
significant difference with irradiated parental PEO1 cells (p<0.05, unpaired t test).  
Scale bar = 20 µm. Counterstains for the DNA-specific dye 4’, 
6-diamidino-2-phenylindole dihydrochloride (DAPI) are also shown. 
 
Figure 4. BRCA2 restoration is critical for acquired drug resistance. (Full-length 
blots are presented in Supplemental Fig. S5D) 
A. BRCA2 western blotting of PEO1, PEO4, C4-2, C4-5, and C4-11 cells treated with 
indicated siRNA. BRCA2 siRNA #1 was used in this experiment. 
B. Cisplatin sensitivity assessed by crystal violet assay. PEO4, C4-2 and C4-5 were 
resistant to cisplatin. BRCA2 siRNA (#1)- treated PEO4, C4-2 and C4-5 cells are 
cisplatin-sensitive compared to control siRNA-treated cells. (p<0.05, LD50 data were 
compared by unpaired t test). BRCA2 siRNA had no effect on cisplatin sensitivity of 
PEO1 and C4-11 cells. (mean ± SEM, n=3) 
C. AG14361 sensitivity assessed by crystal violet assay. PEO4, C4-2 and C4-5 were 
resistant to AG14361. BRCA2 siRNA (#1)-treated PEO4, and C4-2 cells were 
AG14361-sensitive compared to control siRNA-treated cells (p<0.05, LD50 data were 
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compared by unpaired t test). BRCA2 siRNA (#1)-treated C4-5 cells tended to be 
AG14361-sensitive compared to control siRNA-treated cells, but the difference is not 
statistically significant (p=0.067). BRCA2 siRNA (#1) had no effect on AG14361 
sensitivity of PEO1 and C4-11 cells. (mean ± SEM, n=3) 
 
 
 
 
 
 




